Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells
Abstract Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of white blood cells. Tyrosine kinase inhibitors (TKIs) are the standard treatment; however, resistance to BCR::ABL1 mutations remains challenging. WEE1, a checkpoint k...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer
2025-07-01
|
| Серии: | Discover Oncology |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1007/s12672-025-03036-7 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|